Efficacy of a moxidectin/imidacloprid spot-on formulation (Advocate
Animals
Cat Diseases
/ drug therapy
Cats
Drug Combinations
Feces
/ parasitology
Female
Greece
Larva
/ drug effects
Macrolides
/ therapeutic use
Male
Metastrongyloidea
/ drug effects
Neonicotinoids
/ therapeutic use
Nitro Compounds
/ therapeutic use
Respiratory Tract Infections
/ drug therapy
Strongylida Infections
/ drug therapy
Cat
Moxidectin
Treatment
Troglostrongylus brevior
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
04 Nov 2019
04 Nov 2019
Historique:
received:
10
06
2019
accepted:
22
10
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
1
1
2020
Statut:
epublish
Résumé
Troglostrongylus brevior is a lungworm of wild felids that recently has been recognized as agent of severe respiratory disease in domestic cats in Mediterranean and Balkan countries. Nevertheless, the information on treatment options for feline troglostrongylosis is still poor. The aim of this pilot field trial was to evaluate the efficacy of the spot-on formulation containing 1% w/v moxidectin and 10% w/v imidacloprid (Advocate The trial was a negative control, multicentre, clinical efficacy study conducted according to the standards of Good Scientific Practice (GSP). Sixteen cats in two study sites, naturally infected with T. brevior, were allocated to an untreated control group (G1, n = 8) or a treatment group (G2, n = 8), according to a randomization list. Animals assigned to G2 were treated with Advocate All G2 cats were negative for T. brevior L1 at the first post-treatment evaluation (100% efficacy) while G1 cats were persistently shedding L1. The difference of the mean number of L1 per gram between G2 and G1 was statistically significant (P < 0.001). All G1 cats were negative (100% efficacy) for T. brevior L1 at the first post-rescue-treatment evaluation. Therefore, treatment efficacy at study completion was 100% in both groups in terms of stopping the L1 shedding in the faeces of the animals. No adverse effects were observed during the study. These results indicate that Advocate
Sections du résumé
BACKGROUND
BACKGROUND
Troglostrongylus brevior is a lungworm of wild felids that recently has been recognized as agent of severe respiratory disease in domestic cats in Mediterranean and Balkan countries. Nevertheless, the information on treatment options for feline troglostrongylosis is still poor. The aim of this pilot field trial was to evaluate the efficacy of the spot-on formulation containing 1% w/v moxidectin and 10% w/v imidacloprid (Advocate
METHODS
METHODS
The trial was a negative control, multicentre, clinical efficacy study conducted according to the standards of Good Scientific Practice (GSP). Sixteen cats in two study sites, naturally infected with T. brevior, were allocated to an untreated control group (G1, n = 8) or a treatment group (G2, n = 8), according to a randomization list. Animals assigned to G2 were treated with Advocate
RESULTS
RESULTS
All G2 cats were negative for T. brevior L1 at the first post-treatment evaluation (100% efficacy) while G1 cats were persistently shedding L1. The difference of the mean number of L1 per gram between G2 and G1 was statistically significant (P < 0.001). All G1 cats were negative (100% efficacy) for T. brevior L1 at the first post-rescue-treatment evaluation. Therefore, treatment efficacy at study completion was 100% in both groups in terms of stopping the L1 shedding in the faeces of the animals. No adverse effects were observed during the study.
CONCLUSIONS
CONCLUSIONS
These results indicate that Advocate
Identifiants
pubmed: 31685011
doi: 10.1186/s13071-019-3760-9
pii: 10.1186/s13071-019-3760-9
pmc: PMC6829829
doi:
Substances chimiques
Drug Combinations
0
Macrolides
0
Neonicotinoids
0
Nitro Compounds
0
imidacloprid
3BN7M937V8
moxidectin
NGU5H31YO9
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
519Subventions
Organisme : Bayer HealthCare
ID : Project 10163
Références
Parasit Vectors. 2019 Mar 12;12(1):97
pubmed: 30867041
Front Vet Sci. 2018 Jun 20;5:126
pubmed: 29974053
Parasit Vectors. 2015 Nov 14;8:590
pubmed: 26577206
Parasitol Res. 2014 Feb;113(2):613-8
pubmed: 24271082
J Feline Med Surg. 2017 Oct;19(10):1017-1029
pubmed: 27694367
Parasitol Res. 2009 Aug;105 Suppl 1:S55-62
pubmed: 19575226
Int J Parasitol. 2017 Aug;47(9):517-528
pubmed: 28455237
Parasitology. 2013 Jun;140(7):821-4
pubmed: 23552474
Parasit Vectors. 2012 Aug 23;5:178
pubmed: 22916686
Parasitol Res. 2009 Aug;105 Suppl 1:S83-9
pubmed: 19575229
Vet Parasitol. 2014 May 28;202(3-4):104-12
pubmed: 24566126
Trends Parasitol. 2013 Sep;29(9):423-30
pubmed: 23928099
Res Vet Sci. 2015 Oct;102:223-7
pubmed: 26412548
J Feline Med Surg. 2016 Jan;18(1):7-20
pubmed: 26733545
Vet Parasitol. 2015 Apr 30;209(3-4):273-7
pubmed: 25819917
Int J Parasitol. 2019 May;49(6):449-453
pubmed: 30904621
J Parasitol. 2018 Aug;104(4):418-423
pubmed: 29558250